Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals Ltd (QNRX)
:QNRX
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.46Last Year’s EPS
-2.08Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -54.79%
|Next Earnings Date:Mar 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Company Guidance
During the Q4 2023 earnings call for Quoin Pharmaceuticals (QNRX), key guidance included updates on clinical trials for QRX003, a potential treatment for Netherton syndrome. The company implemented several FDA-cleared protocol amendments, including increasing study size, altering dosing frequency, and lowering eligibility age to 14 years. They have 9 commercial partnerships covering 61 countries and completed a $6.5 million public offering, with an $8 million equity line of credit to extend their cash runway into the second half of 2026. Despite a net loss of $8.7 million for 2023, Quoin remains the only company with an open IND for Netherton syndrome, positioning itself for a pivotal year in 2024.Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Successful Protocol Amendments
The FDA cleared several protocol amendments, including increasing study sizes, changing dosing frequency, and lowering eligibility age to 14 years. These changes aim to generate more robust data sets and potentially expedite recruitment.
Strong Commercial Partnerships
Quoin has entered into 9 commercial partnerships covering 61 countries, which will facilitate a global launch of QRX003 once approved. This global network is unprecedented for a company of Quoin's size.
Positive Financial Position
Quoin completed a $6.5 million public offering, and entered an $8 million equity line of credit, extending the cash runway into the second half of 2026. The net loss decreased from $9.4 million in 2022 to $8.7 million in 2023.
---
QNRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
QNRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $0.73 | $0.69 | -5.48% |
| Aug 08, 2024 | $0.56 | $0.52 | -7.14% |
| May 09, 2024 | $0.79 | $0.80 | +1.27% |
| Mar 13, 2024 | $1.16 | $1.00 | -13.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Quoin Pharmaceuticals Ltd (QNRX) report earnings?
Quoin Pharmaceuticals Ltd (QNRX) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Quoin Pharmaceuticals Ltd (QNRX) earnings time?
Quoin Pharmaceuticals Ltd (QNRX) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QNRX EPS forecast?
QNRX EPS forecast for the fiscal quarter 2024 (Q4) is -0.46.
---